SynthesisActa neurologica Scandinavica2020
Cannabidiol efficacy independent of clobazam: Meta-analysis of four randomized controlled trials.
Synthesis in Acta neurologica Scandinavica, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 3 syntheses or guidelines pooled it, 65 citations in OpenAlex.
- Update on Cannabidiol Clinical Toxicity and Adverse Effects: A Systematic Review.Current neuropharmacology · 2023Pooled it
- Cannabidiol in conjunction with clobazam: analysis of four randomized controlled trials.Acta neurologica Scandinavica · 2021Pooled it
- Cannabidiol efficacy independent of clobazam: Meta-analysis of four randomized controlled trials.Acta neurologica Scandinavica · 2020Pooled it
- Cannabidiol Lacks Direct Effect on Cortical Excitability: A Randomized, Double Blind, Placebo Controlled, 3-Way Crossover Trial.Clinical pharmacology and therapeutics · 2026Trial
- Cannabidiol as an Adjunctive Treatment for Acute Bipolar Depression: A Pilot Study: Le cannabidiol comme traitement d'appoint de la dépression bipolaire aiguë : une étude pilote.Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2024Trial
- Time to onset of cannabidiol (CBD) treatment effect in Lennox-Gastaut syndrome: Analysis from two randomized controlled trials.Epilepsia · 2021Trial
- Cannabinoids and drug-drug pharmacokinetic interactions: Deciphering the risks.British journal of clinical pharmacology · 2026Review
- Editorial: Cannabidiol: perspectives on drug-resistant epilepsy management.Frontiers in pharmacology · 2026Article
- Recent Advances in the Management of Seizures in Children.Paediatric drugs · 2026Review
- Retrospective Multicenter Chart Review Study of Adjunctive Cannabidiol for Seizures Associated with Lennox-Gastaut Syndrome, Dravet Syndrome and Tuberous Sclerosis Complex.Neurology and therapy · 2025Article
- UK Medical Cannabis Registry: A Clinical Outcomes Analysis for Epilepsy.Brain and behavior · 2025Observational
- 19 patients report seizure freedom with medical cannabis oil treatment for drug-resistant epilepsy: a case series.Frontiers in neuroscience · 2025Article
- CBD in the Treatment of Epilepsy.Molecules (Basel, Switzerland) · 2024Review
- Beyond CBD: Inhibitory effects of lesser studied phytocannabinoids on human voltage-gated sodium channels.Frontiers in physiology · 2023Article
- The Endocannabinoid System in Glial Cells and Their Profitable Interactions to Treat Epilepsy: Evidence from Animal Models.International journal of molecular sciences · 2021Review
- Time to onset of cannabidiol treatment effects in Dravet syndrome: Analysis from two randomized controlled trials.Epilepsia · 2021Article
- Cannabis and Athletic Performance.Sports medicine (Auckland, N.Z.) · 2021Review
- The Pharmacoresistant Epilepsy: An Overview on Existent and New Emerging Therapies.Frontiers in neurology · 2021Review
- Towards Better Delivery of Cannabidiol (CBD).Pharmaceuticals (Basel, Switzerland) · 2020Review
- The Effects of Cannabinoids on Sleep.Journal of primary care & community healthReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
Abstract
objectiveThe efficacy of cannabidiol (CBD) with and without concomitant clobazam (CLB) was evaluated in stratified analyses of four large randomized controlled trials, two in Lennox-Gastaut syndrome, and two in Dravet syndrome.
methodsEach trial of CBD (Epidiolex
resultsThe meta-analysis favored CBD vs. placebo regardless of CLB use. The treatment ratio (95% CI) of CBD over placebo for the average reduction in seizure frequency was 0.59 (0.52, 0.68; P < .0001) with CLB and 0.85 (0.73, 0.98; P = .0226) without CLB, and the 50% responder rate odds ratio (95% CI) was 2.51 (1.69, 3.71; P < .0001) with CLB and 2.40 (1.38, 4.16; P = .0020) without CLB. Adverse events (AEs) related to somnolence, rash, pneumonia, or aggression were more common in patients with concomitant CLB. There was a significant exposure/response relationship for CBD and its active metabolite.
conclusionsThese results indicate CBD is efficacious with and without CLB, but do not exclude the possibility of a synergistic effect associated with the combination of agents. The safety and tolerability profile of CBD without CLB show a lower rate of certain AEs than with CLB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.